On July 10, 2020, Poseida completed its initial public offering (“IPO”), issuing 14 million shares of common stock with a price of $16.00 per share.  On August 18, 2020, it was disclosed by Poseida that a clinical hold was placed on Poseida’s Phase 1 clinical trial evaluating the autologous CAR-T therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer by the U.S. Food and Drug Administration (“FDA”).  This hold was placed on the trial by the FDA in order to investigate a patient death that occurred in late July.  Poseida’s stock price fell $3.94 per share, or 30.31%, on this news, closing at $9.06 per share on August 18, 2020.

Poseida Therapeutics, Inc.

Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.

Are you a current or former employee of the company?*YesNo


+Additional Purchases


+Additional Sales

If you prefer, you may submit your transaction information or comments/questions in the box below:

There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.

We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.

If you choose to take no action, you can remain an absent class member.

Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.

The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Portnoy Law Firm
Lesley F. Portnoy, Esq.,
Office: 310.692.8883
8240 Beverly Blvd., Suite 9
Los Angeles, CA 90048